Skip to main content
Erschienen in: Skeletal Radiology 1/2012

01.01.2012 | Scientific Article

Atypical diaphyseal femoral fractures—new aspects

verfasst von: Frieda Feldman

Erschienen in: Skeletal Radiology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Post menopausal osteoporotic fractures are a major public health concern worldwide with oral bisphosphonates favored for their prevention and treatment. Recent interest has centered on clinically observed, unusually sited femoral diaphyseal fractures, particularly attributed to alendronate. Their imaging presentations on routine radiographs, alternate imaging modalities, and associated pitfalls in nine fractures in six patients are selectively illustrated by seven fractures in four patients that serve to emphasize the following: (1) Bisphosphonates other than alendronate have been used for treating various bone diseases in children and men as well as osteoporotic women. (2) Effects may differ with each bisphosphonate’s route of administration and prolongation of activity, despite discontinuation. Prior investigations and theoretical mechanisms of bisphosphonates as a class rather than with a specific alendronate association are reviewed to provide a broader basis for evaluating their recently observed clinical and radiographic complications.
Literatur
1.
Zurück zum Zitat Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.PubMedCrossRef Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.PubMedCrossRef
2.
Zurück zum Zitat Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–24.PubMedCrossRef Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–24.PubMedCrossRef
3.
Zurück zum Zitat Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.PubMedCrossRef Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.PubMedCrossRef
4.
Zurück zum Zitat Bilezikian JP. Efficiency of bisphosphonates in reducing fracture risk in post menopausal osteoporosis. Am J Med. 2009;122:S14–21.PubMedCrossRef Bilezikian JP. Efficiency of bisphosphonates in reducing fracture risk in post menopausal osteoporosis. Am J Med. 2009;122:S14–21.PubMedCrossRef
5.
Zurück zum Zitat Tomino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000;85:3109–15.CrossRef Tomino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000;85:3109–15.CrossRef
6.
Zurück zum Zitat Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone. 2003;33:301–7.PubMedCrossRef Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone. 2003;33:301–7.PubMedCrossRef
7.
Zurück zum Zitat La Velle DG. Fractures of the hip. In: Canale ST, editor. Campbell’s operative orthopaedics, vol. 3, 10th ed. St. Louis: Mosby 2002:2873–938. La Velle DG. Fractures of the hip. In: Canale ST, editor. Campbell’s operative orthopaedics, vol. 3, 10th ed. St. Louis: Mosby 2002:2873–938.
8.
Zurück zum Zitat Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80(4):413–5.PubMedCrossRef Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80(4):413–5.PubMedCrossRef
9.
Zurück zum Zitat Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med. 2007;357:2028–39.PubMedCrossRef Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med. 2007;357:2028–39.PubMedCrossRef
10.
Zurück zum Zitat Goh SK, Yang KY, Koh JSB, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89B:349–53. Goh SK, Yang KY, Koh JSB, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89B:349–53.
11.
Zurück zum Zitat Kwek EB, Goh SK, Bee Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef Kwek EB, Goh SK, Bee Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef
12.
Zurück zum Zitat Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef
13.
Zurück zum Zitat Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis, in postmenopausal woman taking alendronate. N Engl J Med. 2008;358:1304–6.PubMedCrossRef Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis, in postmenopausal woman taking alendronate. N Engl J Med. 2008;358:1304–6.PubMedCrossRef
14.
Zurück zum Zitat Porrino Jr JA, Kohl CH, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving biophosphonate therapy. AJR Am J Roentgenol. 2010;194:1061–4.PubMedCrossRef Porrino Jr JA, Kohl CH, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving biophosphonate therapy. AJR Am J Roentgenol. 2010;194:1061–4.PubMedCrossRef
15.
Zurück zum Zitat Bush LA, Chew FS. Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastasis. Radiol Case Rep. 2009;4:1. Bush LA, Chew FS. Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastasis. Radiol Case Rep. 2009;4:1.
16.
Zurück zum Zitat Chan SS, Rosenberg ZS, Chan K, et al. Subtrochanteric femoral fractures in patients receiving long term alendronate therapy: imaging features. A JR Am J Roentgenol. 2010;194:1581–6.CrossRef Chan SS, Rosenberg ZS, Chan K, et al. Subtrochanteric femoral fractures in patients receiving long term alendronate therapy: imaging features. A JR Am J Roentgenol. 2010;194:1581–6.CrossRef
17.
Zurück zum Zitat Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates fur die Beanspruchung der Rohrenknochen. Anat Embryol. 1948;114:1–2.CrossRef Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates fur die Beanspruchung der Rohrenknochen. Anat Embryol. 1948;114:1–2.CrossRef
18.
Zurück zum Zitat Fleisch H, Neuman WF. Mechanism of calcification: role of collagen polyphosphonates and phosphatase. Am J Physiol. 1961;200:1296–300. Fleisch H, Neuman WF. Mechanism of calcification: role of collagen polyphosphonates and phosphatase. Am J Physiol. 1961;200:1296–300.
19.
Zurück zum Zitat Fleisch H, Bisz S. Isolation from urine of pyrophosphates a calcification inhibitor. Am J Physiol. 1962;203:671–5.PubMed Fleisch H, Bisz S. Isolation from urine of pyrophosphates a calcification inhibitor. Am J Physiol. 1962;203:671–5.PubMed
20.
Zurück zum Zitat Fleisch H. In: Bilezikian JP, Rodan GA, editors. Mechanism of action in bisphosphonates in principles of bone biology, vol. 1, 2nd ed. San Diego: Academic Press; 2002. p. 1361–85. Fleisch H. In: Bilezikian JP, Rodan GA, editors. Mechanism of action in bisphosphonates in principles of bone biology, vol. 1, 2nd ed. San Diego: Academic Press; 2002. p. 1361–85.
21.
Zurück zum Zitat Ott SM. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90(3):1897–9.PubMedCrossRef Ott SM. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90(3):1897–9.PubMedCrossRef
22.
Zurück zum Zitat Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–20.PubMedCrossRef Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–20.PubMedCrossRef
23.
Zurück zum Zitat Odvina CV, Zerwekh JE, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.PubMedCrossRef Odvina CV, Zerwekh JE, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.PubMedCrossRef
24.
Zurück zum Zitat Lackman SP, Hughee DE, Coxon FB, et al. Nitrogen-containing bisphosphonates inhibit the mevolonate pathways and prevents posttranslational phenylnation of GTPbinding proteins including RAS. J Bone Miner Res. 1998;13:581–9.CrossRef Lackman SP, Hughee DE, Coxon FB, et al. Nitrogen-containing bisphosphonates inhibit the mevolonate pathways and prevents posttranslational phenylnation of GTPbinding proteins including RAS. J Bone Miner Res. 1998;13:581–9.CrossRef
25.
Zurück zum Zitat Weinstein RS, Roberson PK, Manalagas SC. Giant osteoclast formation and long term oral bisphosphonate therapy N Engl J Med 360;1:53–62. Weinstein RS, Roberson PK, Manalagas SC. Giant osteoclast formation and long term oral bisphosphonate therapy N Engl J Med 360;1:53–62.
26.
Zurück zum Zitat Burr DB, Forwood MR, Fyhrie DP, et al. Perspective: bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12:6–15.PubMedCrossRef Burr DB, Forwood MR, Fyhrie DP, et al. Perspective: bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12:6–15.PubMedCrossRef
27.
Zurück zum Zitat Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475–80.PubMedCrossRef Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475–80.PubMedCrossRef
28.
Zurück zum Zitat Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate induced osteopetrosis. N Engl J Med. 2003;349:457–63.PubMedCrossRef Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate induced osteopetrosis. N Engl J Med. 2003;349:457–63.PubMedCrossRef
Metadaten
Titel
Atypical diaphyseal femoral fractures—new aspects
verfasst von
Frieda Feldman
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Skeletal Radiology / Ausgabe 1/2012
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-011-1130-6

Weitere Artikel der Ausgabe 1/2012

Skeletal Radiology 1/2012 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.